BSD Medical Corporation (NASDAQ:BSDM) today announced that published study results demonstrated improvement in overall survival, tumor response rates, and local tumor control from the addition of hyperthermia therapy, delivered using the BSD-2000 Hyperthermia System, to the standard treatment regimen for 45 patients with high-risk bladder cancer.
The multi-institutional study, titled “Quadrimodal treatment of high-risk T1 and T2 bladder cancer: Transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia,” demonstrated an 80% 3-year overall survival for these high-risk patients who were treated with hyperthermia. The researchers also reported that, in comparison to the results of a previous study they had conducted on trimodal treatment alone for bladder cancer patients, the addition of hyperthermia resulted in a higher overall survival (82% vs. 67% at 5 years) as well as local tumor control rate (81% vs. 63% at 3 years). The researchers reported a significant correlation between the number of hyperthermia treatments and overall survival probability for these patients.
The study was published in Radiotherapy and Oncology by M. Wittlinger, et al., from the Department of Radiation Oncology of the prestigious Erlangen University Medical School in Germany. Radiotherapy and Oncology is the official publication of the European Society for Therapeutic Radiology and Oncology.
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients